Get the Stockscreener App
1.38
4.55%
0.06
After Hours:
1.40
0.02
+1.45%
Celularity Inc stock is traded at $1.38, with a volume of 160.83K.
It is up +4.55% in the last 24 hours and up +72.33% over the past month.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
See More
Previous Close:
$1.32
Open:
$1.33
24h Volume:
160.83K
Relative Volume:
0.04
Market Cap:
$39.95M
Revenue:
$26.55M
Net Income/Loss:
$-91.72M
P/E Ratio:
-0.385
EPS:
-3.584
Net Cash Flow:
$-13.25M
1W Performance:
+5.34%
1M Performance:
+72.33%
6M Performance:
+14.05%
1Y Performance:
-32.35%
1-Day Range:
$1.32
$1.41
1-Week Range:
$1.13
$1.41
52-Week Range:
$0.5601
$2.55
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.38 | 39.95M | 26.55M | -91.72M | -13.25M | -3.584 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Celularity Director Philip Barach Updates Convertible Notes and Warrants, Acquires New Securities - Kalkine Media
Form 4 Celularity Inc For: 25 September - Investing.com India
A note’s share-conversion price fell from $1.66 to $1.50 as a Celularity (CELU) 10% owner bought more notes. - Stock Titan
1,177,000 warrants came with a Celularity (CELU) note purchase by a 10% owner's trust. - Stock Titan
Celularity Secures $10M Initial Financing in Planned $28M Recapitalization - citybiz
Celularity Inc. Announces Appointment of Philip A. Barach to Board - marketscreener.com
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements - Investing News Network
Celularity raises over $10M in debt financing, targets cash flow positive by Q1 2027 - Investing.com
CELU Q4 2025 Earnings: Narrower-Than-Expected Loss Drives 4.84% Share GainRevenue Breakdown Analysis - dars.gov.et
Celularity (NASDAQ: CELU) Achieves Nasdaq Compliance for Bid Price and Market Value - kalkinemedia.com
Form 8K Celularity Inc For: 14 September By Investing.com - Investing.com Nigeria
Celularity regains Nasdaq compliance for bid price and market value - Investing.com
Celularity regains Nasdaq compliance for bid price and market value By Investing.com - Investing.com Nigeria
Celularity Regains Nasdaq Compliance on Bid Price and Market Value Rules - Minichart
CELU Q4 2025 Earnings: Narrower-Than-Expected Loss Fails to Prevent 6.49% Stock DeclineDividend Growth Analysis - dars.gov.et
Celularity (CELU) Stock Slides 8% to $1.54 as Biotech Selling Pressure BuildsMA Cross Alert - siam.in
Celularity and MuseCell Innovations Strike New Jersey Manufacturing Deal Worth Up to $300 Million - BioBuzz
Celularity and MuseCell Innovations strike US manufacturing deal with potential $300m upside & 200 jobs - Indian Pharma Post
Celularity Inc (CELUW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Celularity Manufacturing Deal Could Bring $300 Million, 200 Jobs to Florham Park - Morris Focus
Celularity Inc (CELUW) Peer Comparison – Compare with Others - Value Research
Celularity Inc (CELUW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Celularity (CELU) Stock News & Analysis - TechStock²
Celularity shares jump 138.5% after forecasting $300 million MuseCell manufacturing revenue - TechStock²
Celularity Partners with MuseCell Innovations to Manufacture Allogeneic Cell Therapy Products in the US - BioPharm International
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform - Investing News Network
Why Is Celularity Stock Gaining Thursday? - Benzinga
Florham Park Facility at Center of Cell Therapy Manufacturing Deal Worth Up to $300 Million - centraljersey.com
Celularity and MuseCell Innovations announce manufacturing collaboration - ROI-NJ
$Celularity (CELU.US)$ It's 100% happening, guys - Moomoo
Singapore's MuseCell Innovations announces manufacturing collaboration with Celularity in US - BioSpectrum Asia
Celularity And MuseCell Innovations® Announce U.S. Manufacturing Collaboration For The Dezawa Musecell® Platform - tradingview.com
Celularity to manufacture Dezawa MuseCells for MuseCell Innovations By Investing.com - Investing.com India
Celularity (NASDAQ:CELU): Why Is It in Focus After It provided a fresh Nasdaq listing-compliance update? - Kalkine Media
Celularity Inc. Receives Nasdaq Notice for Late Quarterly Filings, Working to Regain Compliance | CELU Stock News - quiverquant.com
Celularity Provides Update Regarding Nasdaq Listing Compliance - investingnews.com
Celularity (CELU) Latest Quarter: The Bottom-Line Figure Outpaces Its Comparison in the Current Update; Shares Move Lower 2.01% on the DayDividend Earnings Report - vinanet.vn
Celularity (CELU) Technicals: Declines 2.01% to $0.80 in the Current Update; Key Range: Support at $0.76 and Resistance at $0.84 Frame the Range on the DayAnalyst Upgrade Stocks - dars.gov.et
Celularity (CELU) Levels: Finishes 1.41% Down at $0.77 in Latest Trading; Range Check: the Near-Term Reference Band Stretches From $0.73 to $0.81 under the Current SnapshotPrice Momentum Stocks - vinanet.vn
Celularity (CELU) Earnings Snapshot: The EPS Result Is Above Expectation on the Day; Share Move: Shares Move 5.89% Higher in the Current UpdateEPS Surprise History - vinanet.vn
Celularity (CELU) Earnings Snapshot: The EPS Result Is Above Expectation on the Day; Share Move - siam.in
Nexgel’s Celularity Deal: Execution, Integration, and Profitability Risks from $13.3 Million Biomaterials Acquisition - TipRanks
NEXGEL Q2 2026: Revenue $3.69M, Net Loss $2.87M as Company Transitions Post-Acquisition - TradingView
Celularity Delays Quarterly SEC Filing - The Globe and Mail
Celularity (CELU) delays June 2026 10-Q filing amid liquidity and staffing strain - Stock Titan
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy - Stock Titan
CELU Q4 2025 Earnings: Narrower Loss Beats Estimates by 44.44% as Shares Rise 0.72Revenue Inflection Point - careplusvn.com
Celularity (CELU) Slips 2% as Stock Holds Between $0.66 Support and $0.72 ResistanceFast Moving Stocks - dars.gov.et
Celularity Announces Sudden Exit of Chief Commercial Officer - The Globe and Mail
Celularity Inc. Files Form 8-K as Emerging Growth Company on NASDAQ CELU Shares - minichart.com.sg
Celularity removes chief commercial officer Rick Gonzalez effective immediately - Investing.com
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):